Our team (Walker, PI) was awarded a grant by the National Institutes of Health through The Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative.
In this grant – Noninvasive Biomarkers to Advance Emerging DBS Electrode Technologies in Parkinson's Disease – we are investigating a new DBS technology made by Boston Scientific that could provide greater improvement in motor symptoms and quality of life than routine care.This allows greater freedom to adjust a patient’s stimulator settings. Although not yet approved by the Food and Drug Administration of the United States, this new DBS system has been approved and in clinical use in Europe since 2015.
Our overall goal is to pioneer new DBS technology to optimize improvement in motor symptoms and quality of life in patients with Parkinson’s disease.